All In Biotech

Drug Trial Radar · NCT03985943

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 941 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

941

Actual

Start

Jun 27, 2019

Primary completion

Dec 29, 2021

Study completion Aug 11, 2022

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jun 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Conditions

  • Moderate-to-Severe Atopic Dermatitis

Interventions

  • PlaceboDrug

    Placebo

  • NemolizumabDrug

    Nemolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) PopulationTime frame: Week 16
  2. Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus PopulationTime frame: Week 16
  3. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT PopulationTime frame: Week 16
  4. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus PopulationTime frame: Week 16

Locations

174 sites in 14 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site 8880

    North Little Rock, Arkansas

  • Galderma Investigational Site 8578

    Cerritos, California

  • Galderma Investigational Site 8636

    Fountain Valley, California

  • Galderma Investigational Site 8888

    Fullerton, California

  • Galderma Investigational Site 8686

    Lomita, California

  • Galderma Investigational Site 8674

    Los Angeles, California

  • Galderma Investigational Site 8125

    San Francisco, California

  • Galderma Investigational Site 8895

    Santa Ana, California

  • Galderma Investigational Site 8608

    Santa Monica, California

  • Galderma Investigational Site 8897

    Brandon, Florida

  • Galderma Investigational Site 8805

    Cape Coral, Florida

  • Galderma Investigational Site 8902

    Doral, Florida

  • Galderma Investigational Site 8804

    Hialeah, Florida

  • Galderma Investigational Site 8711

    Jacksonville, Florida

  • Galderma Investigational Site 8710

    Miami, Florida

  • Galderma Investigational Site 8801

    Miami, Florida

  • Galderma Investigational Site 8737

    Miami, Florida

  • Galderma Investigational Site 8708

    Miami, Florida

  • Galderma Investigational Site 8806

    Miami Lakes, Florida

  • Galderma Investigational Site 8800

    Miami Lakes, Florida

  • Galderma Investigational Site 8734

    Pembroke Pines, Florida

  • Galderma Investigational Site 8744

    Macon, Georgia

  • Galderma Investigational Site 8728

    Newnan, Georgia

  • Galderma Investigational Site 8887

    Union City, Georgia

  • Galderma Investigational Site 8890

    Blackfoot, Idaho

  • Galderma Investigational Site 8819

    Nampa, Idaho

  • Galderma Investigational Site 8571

    Skokie, Illinois

  • Galderma Investigational Site 8712

    Skokie, Illinois

  • Galderma Investigational Site 8142

    Indianapolis, Indiana

  • Galderma Investigational Site 8771

    Louisville, Kentucky

  • Galderma Investigational Site 8882

    Bangor, Maine

  • Galderma Investigational Site 8743

    Ann Arbor, Michigan

  • Galderma Investigational Site 8512

    Bay City, Michigan

  • Galderma Investigational Site 8155

    Troy, Michigan

  • Galderma Investigational Site 8748

    Ypsilanti, Michigan

  • Galderma Investigational Site 8521

    Saint Joseph, Missouri

  • Galderma Investigational Site 8718

    Missoula, Montana

  • Galderma Investigational Site 8810

    Omaha, Nebraska

  • Galderma Investigational Site 8740

    Henderson, Nevada

  • Galderma Investigational Site 8242

    Brooklyn, New York

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.